
    
      Patients who meet the inclusion and exclusion criteria will be enrolled into the research.
      The participants will voluntarily choose to enter the experimental group or the control group
      with full informed consent. The control group will continue with the original regimen, while
      the study group will switch to tenofovir alafenamide fumarate antiviral therapy. Each group
      will enroll 100 participants.
    
  